[go: up one dir, main page]

SG11201909646TA - Trem2 antigen binding proteins and uses thereof - Google Patents

Trem2 antigen binding proteins and uses thereof

Info

Publication number
SG11201909646TA
SG11201909646TA SG11201909646TA SG11201909646TA SG 11201909646T A SG11201909646T A SG 11201909646TA SG 11201909646T A SG11201909646T A SG 11201909646TA SG 11201909646T A SG11201909646T A SG 11201909646TA
Authority
SG
Singapore
Prior art keywords
california
antigen binding
binding proteins
international
trem2
Prior art date
Application number
Other languages
English (en)
Inventor
Ian Foltz
Shilpa Sambashivan
Irwin Chen
Susie Miki Harris
Warshaviak Dora Toledo
Ian Driver
Daniel Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11201909646TA publication Critical patent/SG11201909646TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201909646T 2017-04-21 2018-04-20 Trem2 antigen binding proteins and uses thereof SG11201909646TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762488691P 2017-04-21 2017-04-21
US201762530753P 2017-07-10 2017-07-10
US201762580400P 2017-11-01 2017-11-01
PCT/US2018/028691 WO2018195506A1 (fr) 2017-04-21 2018-04-20 Protéines de liaison à un antigène anti-trem2 et leurs utilisations

Publications (1)

Publication Number Publication Date
SG11201909646TA true SG11201909646TA (en) 2019-11-28

Family

ID=63856168

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909646T SG11201909646TA (en) 2017-04-21 2018-04-20 Trem2 antigen binding proteins and uses thereof

Country Status (21)

Country Link
US (2) US11186636B2 (fr)
EP (2) EP3612218B1 (fr)
JP (2) JP7252134B2 (fr)
KR (2) KR20250027855A (fr)
CN (1) CN110709100A (fr)
AU (2) AU2018254600B2 (fr)
BR (1) BR112019021991A2 (fr)
CA (1) CA3060409A1 (fr)
CL (2) CL2019003000A1 (fr)
CO (1) CO2019012998A2 (fr)
CR (2) CR20210171A (fr)
ES (1) ES3035028T3 (fr)
JO (1) JOP20190248A1 (fr)
MA (1) MA52273A (fr)
MX (2) MX2019012364A (fr)
PE (2) PE20200485A1 (fr)
PH (1) PH12019502356A1 (fr)
SG (1) SG11201909646TA (fr)
TW (2) TWI812619B (fr)
UY (1) UY37698A (fr)
WO (1) WO2018195506A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019028292A1 (fr) 2017-08-03 2019-02-07 Alector Llc Anticorps anti-trem2 et leurs procédés d'utilisation
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020112889A2 (fr) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Procédés de traitement du métabolisme lipidique dérégulé
US12351629B2 (en) 2018-12-10 2025-07-08 Mor Research Applications Ltd. TREM2 antibodies and uses thereof
EP3917620A4 (fr) * 2019-02-01 2023-02-08 Avrobio, Inc. Compositions et procédés de traitement de troubles neurocognitifs
TWI879756B (zh) * 2019-02-20 2025-04-11 美商戴納立製藥公司 抗ｔｒｅｍ２抗體及其使用方法
WO2020194317A1 (fr) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Méthode de traitement de troubles liés aux lipides
US20220267444A1 (en) * 2019-08-02 2022-08-25 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
IL294655A (en) * 2020-01-13 2022-09-01 Denali Therapeutics Inc Anti-trem2 antibodies and methods of use thereof
TWI890727B (zh) * 2020-01-13 2025-07-21 美商戴納立製藥公司 抗trem2 抗體及其使用方法
JP2023510994A (ja) * 2020-01-20 2023-03-16 中外製薬株式会社 リガンド結合融合タンパク質
WO2021173565A1 (fr) 2020-02-24 2021-09-02 Alector Llc Procédés d'utilisation d'anticorps anti-trem2
KR20230005848A (ko) * 2020-04-03 2023-01-10 알렉터 엘엘씨 항-trem2 항체의 사용 방법
CR20220559A (es) * 2020-05-04 2023-08-18 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
IL300327A (en) * 2020-08-05 2023-04-01 Vigil Neuroscience Inc Treatment of diseases associated with colony-stimulating factor receptor 1 dysfunction using TREM2 agonists
MX2023006598A (es) * 2020-12-03 2023-08-22 Amgen Inc Biomarcadores agonistas del trem2 y métodos para usarlos.
JP2023552553A (ja) * 2020-12-04 2023-12-18 ビジル・ニューロサイエンス・インコーポレイテッド Ｔｒｅｍ２アゴニストを使用した、ａｔｐ結合カセットトランスポーター１機能不全に関連する疾患の治療
WO2023047100A1 (fr) * 2021-09-21 2023-03-30 Quell Therapeutics Ltd Récepteur antigénique chimérique anti-trem2
TW202330614A (zh) * 2021-11-22 2023-08-01 美商維佳神經科學有限公司 抗ｔｒｅｍ２抗體及其用途
AU2022413364A1 (en) 2021-12-17 2024-07-25 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
EP4482523A1 (fr) 2022-02-23 2025-01-01 Alector LLC Méthodes d'utilisation d'anticorps anti-trem2
WO2023192288A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation
WO2023192282A1 (fr) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Méthodes de traitement de l'hypométabolisme du glucose cérébral
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
EP4583971A1 (fr) 2022-09-06 2025-07-16 Institut National de la Santé et de la Recherche Médicale Agonistes de trem-2 pour le traitement du syndrome de marfan
WO2024249954A1 (fr) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Formulations et compositions de nanoparticules lipidiques
WO2024253420A1 (fr) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 Anticorps humain se liant de manière spécifique à la protéine trem2 humaine et son utilisation
WO2025015713A1 (fr) * 2023-07-19 2025-01-23 成都优洛生物科技有限公司 Anticorps humanisé anti-trem2, fragment de liaison à l'antigène de celui-ci et utilisation associée
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025076127A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
WO2025166058A1 (fr) * 2024-01-31 2025-08-07 Alector Llc Protéines multispécifiques se liant au trem2 et au récepteur de la transferrine et leurs utilisations
WO2025179294A2 (fr) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Amplification d'ingénierie immunitaire
CN118420764A (zh) * 2024-04-02 2024-08-02 上海宏成药业有限公司 抗trem2抗体及其用途

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2111348A1 (fr) 1991-06-14 1992-12-23 John S. Logan Production d'hemoglobine humaine dans des porcs transgeniques
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO1994002602A1 (fr) 1992-07-24 1994-02-03 Cell Genesys, Inc. Production d'anticorps xenogeniques
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
EP0904107B1 (fr) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
PT942968E (pt) 1996-12-03 2008-03-27 Amgen Fremont Inc Anticorpos totalmente humanos que se ligam ao egfr
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
WO1998039446A2 (fr) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 proteines humaines secretees
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2000000610A2 (fr) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Proteines contenant un peptide signal humain
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
ES2528794T3 (es) 2000-04-11 2015-02-12 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
CA2431177C (fr) 2000-12-08 2015-04-14 Baylor College Of Medicine Variant d'epissage de trem-1 utile pour modifier des reactions immunitaires
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (fr) 2001-03-20 2013-11-12 Marco Colonna Nouveau recepteur trem (recepteur activateur exprime dans les cellules myeloides) et ses utilisations
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US20030077282A1 (en) 2001-10-12 2003-04-24 Bigler Michael Eric Use of bispecific antibodies to regulate immune responses
AU2003215761A1 (en) 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2489145A1 (fr) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Substance sensibilisante a l'insuline
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
ATE501171T1 (de) * 2004-05-27 2011-03-15 Crucell Holland Bv Bindungsmoleküle, die dazu fähig sind, das tollwutvirus zu neutralisieren, und anwendungen davon
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
KR20060135280A (ko) 2005-06-24 2006-12-29 전남대학교산학협력단 선천성 면역에 관여하는 트렘-2의 클로닝
AU2006265113A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CN103073639A (zh) 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
WO2007146968A2 (fr) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Protéines de liaison monocaténaires polyvalentes dotées d'une fonction d'effecteur
CA2551163A1 (fr) 2006-07-17 2008-01-17 Boehringer Ingelheim International Gmbh Methodes pour le traitement de maladies inflammatoires, de maladies autoimmunes ou de maladies de resorption osseuse
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
JP2010516678A (ja) 2007-01-16 2010-05-20 ワイス エルエルシー Ｔｒｅｍ−１による炎症治療、検出およびモニタリング
WO2008110348A1 (fr) 2007-03-12 2008-09-18 Esbatech Ag Ingénierie et optimisation basées sur la séquence d'anticorps à une seule chaîne
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
SI2158315T1 (sl) 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
GR1007327B (el) 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
ES3006441T3 (en) 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CA2709847C (fr) 2008-01-07 2018-07-10 Amgen Inc. Methode de fabrication de molecules heterodimeres fc d'anticorps utilisant les effets de conduite electrostatique
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
WO2010045479A1 (fr) 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Compositions micellaires et liposomales de phospholipide et leurs utilisations
WO2010125110A1 (fr) 2009-04-28 2010-11-04 Life & Brain Gmbh Procédé permettant d'obtenir des cellules précurseurs microgliales humaines à partir de cellules souches pluripotentes
WO2010132370A2 (fr) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Peptides solubles de la famille trem-1 et procédés d'utilisation
RU2012101999A (ru) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
WO2011047097A2 (fr) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition de la signalisation des récepteurs trem avec des variants peptidiques
CN102038698A (zh) 2009-10-14 2011-05-04 山东绿叶天然药物研究开发有限公司 莫诺苷的新用途
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2496600A1 (fr) * 2009-11-04 2012-09-12 Fabrus LLC Procédés pour l'optimisation d'anticorps basée sur la maturation d'affinité
CN102127168A (zh) 2010-01-19 2011-07-20 中国人民解放军第二军医大学 一种髓样细胞表达激发受体-1的重组融合蛋白及其应用
KR20110086460A (ko) 2010-01-22 2011-07-28 한국교원대학교산학협력단 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
CN103153327B (zh) 2010-04-08 2016-01-20 国家健康与医学研究院 衍生自trem样转录1(tlt-1)的抑制肽和其用途
CA2798120A1 (fr) 2010-04-30 2011-11-03 Paul P. Tamburini Anticorps dont l'antigenicite pour l'humain est reduite
WO2012016333A1 (fr) 2010-08-06 2012-02-09 University Health Network Biomarqueurs du paludisme
US20130130354A1 (en) 2010-09-28 2013-05-23 CTI Salud S.A. Novel genes and uses thereof, expression profile of colon, gastric and pancreatic cancer
EP2655415A4 (fr) 2010-12-22 2016-03-09 Abbvie Inc Protéines de liaison à trois domaines variables et leurs utilisations
EP2654792A4 (fr) 2010-12-22 2016-05-11 Abbvie Inc Protéines de liaison à une demi-immunoglobuline et leurs utilisations
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AU2012229251A1 (en) 2011-03-11 2013-09-12 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
KR20120112973A (ko) 2011-04-04 2012-10-12 전남대학교산학협력단 비만 또는 제 2형 당뇨의 예방 또는 치료용 조성물
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6216321B2 (ja) 2011-10-11 2017-10-18 ジェネンテック， インコーポレイテッド 二重特異性抗体の構築の改善
RU2014120465A (ru) 2011-10-21 2015-11-27 Стемдженикс, Инк Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
EP2776061B1 (fr) 2011-11-07 2019-08-14 MedImmune, LLC Protéines de liaison multispécifiques et multivalentes et leurs utilisations
CA3111357A1 (fr) 2011-12-23 2013-06-27 Pfizer Inc. Regions constantes d'anticorps modifies pour conjugaison specifique a un site, et leurs procedes et utilisations
TWI450727B (zh) 2011-12-29 2014-09-01 Ind Tech Res Inst 抗人類輸鐵蛋白受體的單域抗體與其應用
CN102517287B (zh) 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
KR20130114951A (ko) 2012-04-10 2013-10-21 한양대학교 산학협력단 폴리감마글루탐산을 포함하는 Ｔｈ17 매개성 질환 예방 또는 치료용 조성물
HRP20200875T8 (hr) 2012-09-07 2021-04-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitorni peptidi porijeklom od aktivirajućeg receptora eksprimiranog na mijeloidnim stanicama-1 (trem-1)-sličnog transkripta 1 (tlt-1) i nihove upotrebe
KR101947702B1 (ko) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
CA2887825A1 (fr) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Anticorps avec des domaines fc d'igg modifies
WO2014074942A1 (fr) 2012-11-08 2014-05-15 Illumina, Inc. Variants de risque de développer la maladie d'alzheimer
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9066928B1 (en) 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
EP3594240B1 (fr) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anticorps du récepteur anti-transferrine et procédés d'utilisation
KR20150010326A (ko) 2013-07-19 2015-01-28 전남대학교산학협력단 비만 및 제 2형 당뇨 또는 지방간의 예방 또는 치료용 바이아릴아마이드를 포함한 유도체 화합물
KR101402921B1 (ko) 2013-08-28 2014-06-02 전남대학교산학협력단 비만 또는 제 2형 당뇨의 치료를 위한 레스베라톨 유도체의 이용
CA2825821A1 (fr) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. Derives d'acide 1-phenylalcane-carboxylique pour le traitement de la maladie d'alzheimer et la sclerose en plaques
WO2015037000A1 (fr) 2013-09-11 2015-03-19 Compugen Ltd Polypeptides vstm5 et leurs utilisations en tant que médicament pour le traitement du cancer, de maladies infectieuses et de maladies de type immunitaire
CN103555829B (zh) 2013-10-12 2015-10-21 厦门人瑞生物医药科技有限公司 一种检测trem2基因r47h突变的探针、试剂盒和方法
US20160327572A1 (en) 2014-01-06 2016-11-10 Children's Medical Center Corporation Biomarkers for Dementia and Dementia Related Neurological Disorders
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN103866041A (zh) 2014-04-04 2014-06-18 厦门大学 帕金森病和脑白质疏松症的突变检测试剂盒及其检测方法
SMT201900160T1 (it) 2014-04-11 2019-05-10 Medimmune Llc Composti coniugati comprendenti anticorpi ingegnerizzati con cisteina
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR101756417B1 (ko) 2014-08-21 2017-07-10 한국유나이티드제약 주식회사 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물
IL294043B2 (en) 2014-09-28 2024-10-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
US20170334977A1 (en) 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
CN107847504A (zh) 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
WO2016201388A2 (fr) 2015-06-12 2016-12-15 Alector Llc Anticorps anti-cd33 et leurs procédés d'utilisation
EP3307779A2 (fr) 2015-06-12 2018-04-18 Alector LLC Anticorps anti-cd33 et leurs procédés d'utilisation
WO2017007712A1 (fr) 2015-07-04 2017-01-12 Emory University Utilisation d'inhibiteurs de trem-1 pour traiter, éliminer et éradiquer l'infection par le vih-1
WO2017011342A1 (fr) 2015-07-10 2017-01-19 Abbvie Inc. Protéines de liaison modifiées par igm ou ige et leurs utilisations
IL290571B2 (en) * 2015-07-30 2023-03-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
CA2996059A1 (fr) 2015-08-28 2017-03-09 Alector Llc Anticorps anti-siglec-7 et leurs methodes d'utilisation
WO2017058866A1 (fr) 2015-09-28 2017-04-06 Precision Immune, Inc. Anticorps anti-trem2 et leurs utilisations
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法
CN108431041B (zh) 2015-10-29 2022-08-16 艾利妥 抗siglec-9抗体及其使用方法
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
WO2017139638A1 (fr) 2016-02-11 2017-08-17 The Johns Hopkins University Compositions et méthodes pour la neurogenèse
WO2017147509A1 (fr) 2016-02-25 2017-08-31 Marco Colonna Compositions comprenant de la trem2 et leurs procédés d'utilisation
WO2017152102A2 (fr) 2016-03-04 2017-09-08 Alector Llc Anticorps anti-trem1 et leurs méthodes d'utilisation
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
US11078247B2 (en) 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
US11944665B2 (en) 2016-06-01 2024-04-02 University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
US10941200B2 (en) 2016-07-22 2021-03-09 Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev TREM2 cleavage modulators and uses thereof
CN106244682B (zh) 2016-07-29 2019-11-26 中山大学 Trem-2基因在鉴别猪对蓝耳病毒易感性中的应用
CN106636330B (zh) 2016-09-21 2017-12-15 郁金泰 阿尔茨海默病的诊断和治疗药物
AU2017342555A1 (en) 2016-10-14 2019-05-30 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
WO2018107058A1 (fr) 2016-12-09 2018-06-14 Alector Llc Anticorps anti-sirp-alpha et leurs procédés d'utilisation
WO2018119018A1 (fr) 2016-12-23 2018-06-28 Genervon Biopharmaceuticals, LLC Procédés d'utilisation de gm6 dans le diagnostic et le traitement de la maladie d'alzheimer
CN110573167A (zh) 2017-01-12 2019-12-13 杜克大学 用于治疗脱髓鞘疾病的组合物和方法
EP3570883A2 (fr) 2017-01-17 2019-11-27 Yeda Research and Development Co. Ltd Procédés de traitement de maladies neurodégénératives par induction de cellules de microglie associées à une maladie (dam)
US20190365830A1 (en) 2017-01-18 2019-12-05 Evelo Biosciences, Inc. Methods of treating cancer
EP3574018A4 (fr) 2017-01-27 2020-10-07 Silverback Therapeutics, Inc. Conjugués ciblant les tumeurs et leurs méthodes d'utilisation
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US20210293794A1 (en) 2017-02-24 2021-09-23 University Of Hawii Cancer Center Metabolic biomarkers for the identification and characterization of alzheimers disease
JP2020513794A (ja) 2017-02-28 2020-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多能性幹細胞および造血始原細胞からのヒトミクログリア様細胞の分化と使用
WO2018175581A1 (fr) 2017-03-21 2018-09-27 The Jackson Laboratory Souris génétiquement modifiée exprimant apoe4 humaine et trem.p.r47h et procédés d'utilisation associés
KR101936249B1 (ko) 2017-04-04 2019-01-08 경희대학교 산학협력단 쿠마타케닌을 포함하는 암의 예방, 개선 또는 치료용 조성물
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20180318379A1 (en) 2017-05-01 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
WO2018213316A1 (fr) 2017-05-16 2018-11-22 Alector Llc Anticorps anti-siglec-5 et leurs procédés d'utilisation
WO2018218090A1 (fr) 2017-05-24 2018-11-29 Nanosomix, Inc. Détection de biomarqueurs sur des vésicules pour le diagnostic et le pronostic de maladies et de troubles
JP7710827B2 (ja) 2017-06-05 2025-07-22 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
WO2019005637A2 (fr) 2017-06-25 2019-01-03 Systimmune, Inc. Anticorps multipécifiques et procédés de production et d'utilisation associés
CN109206503A (zh) 2017-07-07 2019-01-15 厦门大学 一种蛋白用于制备防治阿尔茨海默病药物的用途
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
BR112020001060A2 (pt) 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase
WO2019028292A1 (fr) 2017-08-03 2019-02-07 Alector Llc Anticorps anti-trem2 et leurs procédés d'utilisation
BR112019023789A2 (pt) 2017-08-03 2020-07-28 Alector Llc anticorpos anti-cd33 e métodos de uso dos mesmos
US20200247889A1 (en) 2017-08-08 2020-08-06 Pionyr Immunotherapeutics, Inc. Compositions and methods for disabling myeloid cells expressing trem1
US20200277373A1 (en) 2017-09-14 2020-09-03 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2019068072A1 (fr) 2017-09-29 2019-04-04 The General Hospital Corporation Méthodes d'identification et de traitement de l'adrénomyéloneuropathie (amn)
CN112481269A (zh) 2017-10-03 2021-03-12 普利维尔治疗公司 用于溶酶体障碍的基因疗法
WO2019079529A1 (fr) 2017-10-17 2019-04-25 The Translational Genomics Research Institute Agonistes de trem2 pour la stimulation de la microglie et des méthodes d'identification
US10597462B1 (en) 2017-11-08 2020-03-24 University Of Puerto Rico Anti-TLT-1 antibody and uses thereof
WO2019095064A1 (fr) 2017-11-15 2019-05-23 UNIVERSITé LAVAL Utilisation d'agents srsf3 pour le traitement et/ou la prévention d'affections neurologiques, du cancer, d'infections bactériennes ou d'infections virales
CN109837330A (zh) 2017-11-28 2019-06-04 上海中优精准医疗科技股份有限公司 一种检测trem2基因多态性的探针及方法
PE20200862A1 (es) 2017-12-12 2020-08-25 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
AU2019222760A1 (en) 2018-02-14 2020-09-10 Yale University Compositions for modulation of a TREM or TREML protein and methods of use
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
EP3768261A1 (fr) 2018-03-22 2021-01-27 NSC THERAPEUTICS GmbH Composés et procédés destinés à être utilisés dans le traitement de troubles médiés par la microglie
EA202092302A1 (ru) 2018-04-02 2021-02-02 Бристол-Майерс Сквибб Компани Антитела к trem-1 и их применения
EP3773543A4 (fr) 2018-04-09 2022-04-06 The General Hospital Corporation Polythérapies pour le traitement de la sclérose latérale amyotrophique et de troubles apparentés
MA52753A (fr) 2018-05-25 2021-04-21 Alector Llc Anticorps anti-sirpa et leurs procédés d'utilisation
CA3100626A1 (fr) 2018-06-08 2019-12-12 Alector Llc Anticorps anti-siglec-7 et leurs methodes d'utilisation
CN108752482B (zh) 2018-06-12 2019-04-30 南京卡提医学科技有限公司 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用
US20210195879A1 (en) 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
BR112020026819A2 (pt) 2018-06-29 2021-04-20 Alector Llc anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
JP2021531751A (ja) 2018-07-12 2021-11-25 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシン経路活性化を有する癌を検出および治療するための方法
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
WO2020018461A1 (fr) 2018-07-16 2020-01-23 The University Of Virginia Patent Foundation Compositions et méthodes pour le diagnostic et le traitement de maladies neurologiques
CN109112214A (zh) 2018-07-27 2019-01-01 复旦大学附属中山医院 模式识别受体trem2在肝癌预后和治疗中的应用
MA53328A (fr) 2018-07-27 2021-06-09 Alector Llc Anticorps anti-siglec-5 et leurs procédés d'utilisation
MA53492A (fr) 2018-08-31 2021-09-15 Alector Llc Anticorps anti-cd33 et leurs méthodes d'utilisation
US20220218652A1 (en) 2018-09-05 2022-07-14 The General Hospital Corporation Methods of treating cytokine release syndrome
CN113164572A (zh) 2018-09-11 2021-07-23 华盛顿大学 抗trem-2激动剂抗体
US20210315816A1 (en) 2018-09-12 2021-10-14 Board Of Regents Of The University Of Nebraska Antimicrobial compositions and methods
BR112021005808A2 (pt) 2018-09-28 2021-07-27 Inotrem uso de níveis de trem-1 solúveis para identificar indivíduos suscetíveis a responder a uma terapia anti-inflamatória
KR102096282B1 (ko) 2018-10-15 2020-04-02 재단법인대구경북과학기술원 재조합 베큘로바이러스를 이용한 인간 ｔｒｅｍ２ 세포막 단백질의 효율적인 정제방법
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN111135185A (zh) 2018-11-02 2020-05-12 杭州星鳌生物科技有限公司 天然免疫激活通过调控髓系细胞触发受体trem2抑制大脑神经慢性炎症
WO2020097395A1 (fr) 2018-11-08 2020-05-14 The Regents Of The University Of California Systèmes et procédés de ciblage de cellules cancéreuses
WO2020112889A2 (fr) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Procédés de traitement du métabolisme lipidique dérégulé
US12351629B2 (en) 2018-12-10 2025-07-08 Mor Research Applications Ltd. TREM2 antibodies and uses thereof
WO2020132230A2 (fr) 2018-12-20 2020-06-25 Genentech, Inc. Fc d'anticorps modifiés et méthodes d'utilisation
CN109646668B (zh) 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
EP3906055A4 (fr) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. Molécules de protéines multispécifiques et leurs utilisations
MA54752A (fr) 2019-01-14 2021-11-24 Univ Virginia Patent Foundation Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
WO2020152607A1 (fr) 2019-01-22 2020-07-30 St. Jude Children's Research Hospital Modulation de la voie d'endocytose associée à lc3 et animaux non humains génétiquement modifiés en tant que modèle de neuro-inflammation et de neurodégénérescence
EP3914071A4 (fr) 2019-01-23 2022-10-19 The Regents of the University of California Cellules rapporteurs de construction génomique humaine et modèles de souris pour cribler des agents thérapeutiques contre des gènes associés à une maladie exprimée par la microglie
EP3917967A4 (fr) 2019-02-01 2023-02-08 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Capteurs de microenvironnement pour réguler l'expression génique modifiée
EP3917623A4 (fr) 2019-02-01 2022-10-19 Avrobio, Inc. Compositions et méthodes pour le traitement de troubles neurocognitifs
EP3917620A4 (fr) 2019-02-01 2023-02-08 Avrobio, Inc. Compositions et procédés de traitement de troubles neurocognitifs
TWI879756B (zh) 2019-02-20 2025-04-11 美商戴納立製藥公司 抗ｔｒｅｍ２抗體及其使用方法
WO2020194317A1 (fr) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Méthode de traitement de troubles liés aux lipides
CN110320368A (zh) 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
CN110241208A (zh) 2019-08-02 2019-09-17 辽宁中医药大学 Trem2作为早期诊断冠心病的分子标志物的应用
CN110511240B (zh) 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
CN110882262A (zh) 2019-11-06 2020-03-17 南京医科大学 一种髓细胞触发受体2的激活用药及其应用
BR112022007944A2 (pt) 2019-11-22 2022-07-12 Lilly Co Eli Anticorpos trem2 e usos dos mesmos
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
CN111184742B (zh) 2020-02-13 2022-06-24 中山大学附属第五医院 Trem-2+t细胞在制备用于治疗结核病药物中的应用

Also Published As

Publication number Publication date
JP7559025B2 (ja) 2024-10-01
CL2019003000A1 (es) 2020-02-14
EP4617286A2 (fr) 2025-09-17
JP2020517249A (ja) 2020-06-18
AU2022221560B2 (en) 2025-09-18
TWI812619B (zh) 2023-08-21
AU2018254600A1 (en) 2019-10-24
TW202423975A (zh) 2024-06-16
CN110709100A (zh) 2020-01-17
AU2018254600B2 (en) 2022-05-26
KR20200018778A (ko) 2020-02-20
CO2019012998A2 (es) 2020-02-18
CL2024003661A1 (es) 2025-04-21
US11186636B2 (en) 2021-11-30
MX2024000156A (es) 2024-01-23
BR112019021991A2 (pt) 2020-06-16
KR102772851B1 (ko) 2025-02-27
EP3612218A4 (fr) 2021-07-28
WO2018195506A1 (fr) 2018-10-25
KR20250027855A (ko) 2025-02-27
PH12019502356A1 (en) 2020-12-07
UY37698A (es) 2018-10-31
AU2022221560A1 (en) 2022-09-22
US20220204611A1 (en) 2022-06-30
MX2019012364A (es) 2019-11-28
JP2022188272A (ja) 2022-12-20
US20210054069A1 (en) 2021-02-25
CA3060409A1 (fr) 2018-10-25
ES3035028T3 (en) 2025-08-28
TW201906628A (zh) 2019-02-16
MA52273A (fr) 2021-04-28
CR20190525A (es) 2020-03-20
JP7252134B2 (ja) 2023-04-04
EP3612218B1 (fr) 2025-04-09
PE20200485A1 (es) 2020-03-03
EP3612218A1 (fr) 2020-02-26
CR20210171A (es) 2021-05-21
PE20250782A1 (es) 2025-03-14
JOP20190248A1 (ar) 2019-10-20

Similar Documents

Publication Publication Date Title
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201908540PA (en) Stable antibody formulation
SG11201906961UA (en) Polypeptide variants and uses thereof
SG11201909541WA (en) Chimeric antibody/t-cell receptor constructs and uses thereof
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201903693QA (en) Polypeptide variants and uses thereof
SG11201906341XA (en) Improved serum albumin binders
SG11201901066UA (en) Novel alkaline stable immunoglobulin-binding proteins
SG11201906264YA (en) Improved serum albumin binders
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201805255TA (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201909728XA (en) Constructs specifically recognizing glypican 3 and uses thereof
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use